Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

被引：1
|
作者：
Clegg, Lindsay
Heerspink, Hiddo L.
Penland, Robert C.
Tang, Weifeng
Boulton, David W.
Bachina, Srinivas
Fox, Robert D.
Fenici, Peter
Thuresson, Marcus
Mentz, Robert J.
Hernandez, Adrian F.
Bethel, M. Angelyn
Holman, Rury R.
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-130-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
    Lardaro, Antonio
    Quarta, Ludovica
    Pagnotta, Stefania
    Sodero, Giorgio
    Mariani, Sandro
    Del Ben, Maria
    Desideri, Giovambattista
    Ettorre, Evaristo
    Baratta, Francesco
    BIOMEDICINES, 2024, 12 (08)
  • [22] Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management
    Katsiki, Niki
    Mikhailidis, Dimitri P.
    Theodorakis, Michael J.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) : 1522 - 1532
  • [23] Higher estimated glomerular filtration rate (eGFR) is associated with improved glycaemic response to sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with Type 2 diabetes and normal renal function: A MASTERMIND study
    Kimmitt, R. A.
    Dennis, J. M.
    Weedon, M.
    Rodgers, L. R.
    Jones, A. G.
    Pearson, E. R.
    Hattersley, A. T.
    Oram, R. A.
    Shields, B. M.
    DIABETIC MEDICINE, 2018, 35 : 35 - 35
  • [24] Correlates and Consequences of an Acute Decline in Estimated Glomerular Filtration Rate in Response to the SGLT-2 Inhibitor Dapagliflozin
    Heerspink, Hiddo J. L.
    Jongs, Niels
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Stefansson, Bergur V.
    Toto, Robert D.
    Greene, Tom
    Wheeler, David C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 726 - 726
  • [25] Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
    Patorno, Elisabetta
    Kim, Dae H.
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Munshi, Medha
    Bessette, Lily G.
    Kim, Seoyoung C.
    DIABETES, 2019, 68
  • [26] TO TREAT OR NOT TO TREAT - THE REAL IMPACT OF SGLT-2 INHIBITORS ON CARDIOVASCULAR RISK
    Timar, Bogdan
    Gaita, Laura
    Timar, Romulus
    INTERDIAB 2016: DIABETES MELLITUS AS CARDIOVASCULAR DISEASE, 2016, : 458 - 466
  • [27] Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
    McGovern, Andrew P.
    Hogg, Michael
    Shields, Beverley M.
    Sattar, Naveed A.
    Holman, Rury R.
    Pearson, Ewan R.
    Hattersley, Andrew T.
    Jones, Angus G.
    Dennis, John M.
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [28] The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
    Starr, Jessica A.
    Pinner, Nathan A.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (05) : 506 - 513
  • [29] Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
    Starr, Jessica A.
    Pinner, Nathan A.
    Lisenby, Katelin M.
    Osmonson, Alyssa
    PHARMACOTHERAPY, 2021, 41 (06): : 526 - 536
  • [30] Role of SGLT2 Inhibitors and GLP-1 Analogs in Cardiovascular Risk Reduction in Type 2 Diabetes
    Rashed, Mostafa Hamdy
    Dauyoumor, Tonbra Deborah
    Corney, Sarah
    Konono, Kimberly
    Joubert, Nadia
    Mohamed, Marwa
    Sukhoo-Pertab, Michon
    Makhomisane, Mobowa
    Njeri, Irene
    Mwita, Julius
    Sefen, Mariam
    Mohamed, Khadija
    Whiley, Nicolette
    WORLD FAMILY MEDICINE, 2021, 19 (12): : 119 - 128
12345